Salud financiera de hoja de balance de Capricor Therapeutics
Salud financiera controles de criterios 6/6
Capricor Therapeutics tiene un patrimonio de los accionistas total de $22.6M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $58.7M y $36.1M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$39.49m |
| Patrimonio | US$22.60m |
| Total pasivo | US$36.13m |
| Activos totales | US$58.73m |
Actualizaciones recientes sobre salud financiera
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Aug 13Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth
Feb 01We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth
Oct 14Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 16Recent updates
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up
May 08Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 03Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Aug 13A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Nov 03Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Aug 10Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth
Feb 01We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth
Oct 14Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result
Sep 25Capricor Therapeutics slumps 9% on $75M stock offering
Jun 21Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 16When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?
Mar 13Capricor signs intellectual property license for COVID-19 serology test platform
Feb 01Capricor and Lonza tie up in DMD development
Jan 12Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19
Nov 24Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($50.9M) de CAPR superan a sus pasivos a corto plazo ($31.3M).
Pasivo a largo plazo: Los activos a corto plazo de CAPR ($50.9M) superan a sus pasivos a largo plazo ($4.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: CAPR está libre de deudas.
Reducción de la deuda: CAPR no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: CAPR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: CAPR dispone de suficiente cash runway para 1.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 1.6% cada año.